Biovica International AB (OSTO:BIOVIC B)
kr 2.6 0.2 (8.33%) Market Cap: 218.54 Mil Enterprise Value: 121.52 Mil PE Ratio: 0 PB Ratio: 1.61 GF Score: 37/100

Q3 2021 Biovica International AB Earnings Call Transcript

Mar 18, 2021 / 09:00AM GMT
Release Date Price: kr41.36 (+6.36%)
Anders Rylander;publ;CEO;Director
Biovica International AB

()-&

Welcome, everyone, to our interim report presentation. So if we go to the next slide, you'll see that it will be me and Cecilia Driving, our CFO, that will perform the presentation.

And if we to the next slide after that, you'll see the agenda. So we'll start with -- or I will start with a short introduction of Biovica. We will go through the highlights for the third quarter in our fiscal year, which we're now presenting. Cecilia will walk through the financial and we will end with a summary and a Q&A where you will be able to ask us questions. And we also have had questions coming by mail before that I will start with. So that's the agenda for today.

So if we move on to the next slide, just a very short background about the company, what we do. So Biovica develops and commercializes blood-based biomarker assays with the purpose to improve monitoring of modern cancer therapies, and I'll get that a little bit to how we do that. We do that through our assay, biomarker

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot